KDJ24002
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
REGN727, SAR-236553, CAS: 1245916-14-6
Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis., PMID:40511660
Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Primary Cardiovascular Prevention in High-Risk Patients: A Systematic Review., PMID:40486443
Association between novel agents targeting proprotein convertase subtilisin/kexin type 9 and cancer incidence., PMID:40447742
Improvement of retinal microvascular function after initiation of lipid-lowering therapy with PCSK9 inhibitors - An observational study., PMID:40360377
Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis., PMID:40358978
Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels., PMID:40351695
RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: A drug-target Mendelian randomization study., PMID:40347490
Effectiveness of alirocumab and evolocumab (PCSK9i) for the treatment of hypercholesterolemia., PMID:40339450
Hypercholesterolemia and cardiovascular disease: the dilemma of effective treatment for target achievement according to guidelines and national healthcare policies and a call to action., PMID:40322779
Alirocumab in Adult Patients With Hyperlipidemia After Liver Transplantation: A Short-term Observation., PMID:40307128
Effect of Alirocumab in Atherosclerotic Plaques-Reply., PMID:40305042
Effect of Alirocumab in Atherosclerotic Plaques., PMID:40305033
Effectiveness and safety of long-term therapy with alirocumab in acute coronary syndrome patients: A single-centre retrospective real-world study., PMID:40289287
Corrigendum to "Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk" [Diabetes Res. Clin. Pract. 222 (2025) 112055]., PMID:40253258
Inadequate Response to PCSK9 Inhibitors., PMID:40250948
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial., PMID:40250826
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis., PMID:40222896
Developing a national implementation strategy for enhancing the detection of familial hypercholesterolemia: An Australian experience., PMID:40221339
Safety and effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition: an updated review., PMID:40202526
Target-Mediated Modeling of Alirocumab in Adolescents and Children ≥8 to <12 Years of Age Using Phase II and III Data., PMID:40136083
Immunotherapy and vaccine-based approaches for atherosclerosis prevention: a systematic review study., PMID:40114074
Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence., PMID:40095683
Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan., PMID:40089775
Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy., PMID:40081501
PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling., PMID:40076547
Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial., PMID:40045751
Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis., PMID:40026525
Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk., PMID:40020784
Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial., PMID:40001082
In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss., PMID:39979532
Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis., PMID:39975967
Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice., PMID:39963241
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?, PMID:39947256
PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose., PMID:39940773
Considerations on the sustainability of hypercholesterolemia treatment in the context of new drugs on the market: data from Campania, Italy., PMID:39921732
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome., PMID:39921475
American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia., PMID:39919851
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial., PMID:39913634
Response to Letter Regarding Article, "Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab"., PMID:39906998
Letter by Natale et al Regarding Article, "Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab"., PMID:39906990
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction., PMID:39906341
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials., PMID:39877671
Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study., PMID:39875772
Efficacy and safety of PCSK9 inhibitors in real life., PMID:39864963
Effect of Alirocumab Monotherapy vs Ezetimibe Plus Statin Therapy on LDL-C Lowering in Veterans With History of ASCVD., PMID:39839705
Cost-Effectiveness Analysis of Inclisiran for the Treatment of Primary Hypercholesterolemia or Mixed Dyslipidemia in Singapore., PMID:39818637
The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis., PMID:39813003
Emerging oral therapeutic strategies for inhibiting PCSK9., PMID:39802651
PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression., PMID:39770423
Lipids, lipid-lowering drugs and the risk of herpes zoster: a Mendelian randomization study., PMID:39755897
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
